CN107001354B - 组蛋白去乙酰酶抑制剂 - Google Patents

组蛋白去乙酰酶抑制剂 Download PDF

Info

Publication number
CN107001354B
CN107001354B CN201580019257.4A CN201580019257A CN107001354B CN 107001354 B CN107001354 B CN 107001354B CN 201580019257 A CN201580019257 A CN 201580019257A CN 107001354 B CN107001354 B CN 107001354B
Authority
CN
China
Prior art keywords
stirred
mixture
500mhz
nmr
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580019257.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107001354A (zh
Inventor
阎云
刘景平
张俊彦
王家仪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Taipei Medical University TMU
Original Assignee
National Health Research Institutes
Taipei Medical University TMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes, Taipei Medical University TMU filed Critical National Health Research Institutes
Publication of CN107001354A publication Critical patent/CN107001354A/zh
Application granted granted Critical
Publication of CN107001354B publication Critical patent/CN107001354B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
CN201580019257.4A 2014-04-11 2015-04-09 组蛋白去乙酰酶抑制剂 Active CN107001354B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461978606P 2014-04-11 2014-04-11
US61/978,606 2014-04-11
PCT/US2015/025084 WO2015157504A1 (en) 2014-04-11 2015-04-09 Histone deacetylase inhibitors

Publications (2)

Publication Number Publication Date
CN107001354A CN107001354A (zh) 2017-08-01
CN107001354B true CN107001354B (zh) 2021-06-22

Family

ID=54288395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580019257.4A Active CN107001354B (zh) 2014-04-11 2015-04-09 组蛋白去乙酰酶抑制剂

Country Status (6)

Country Link
US (1) US10246455B2 (enExample)
EP (1) EP3129373B1 (enExample)
JP (1) JP6726658B2 (enExample)
CN (1) CN107001354B (enExample)
TW (1) TWI573787B (enExample)
WO (1) WO2015157504A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170124602A (ko) 2015-03-13 2017-11-10 포르마 세라퓨틱스 인크. Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물
US10525040B2 (en) * 2015-06-29 2020-01-07 Nantbio, Inc. Compositions and methods of Rit1 inhibition
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN105622605B (zh) * 2016-03-01 2017-10-13 苏州艾缇克药物化学有限公司 一种5‑溴‑7‑氮杂吲哚的合成方法
TWI659949B (zh) 2016-05-16 2019-05-21 臺北醫學大學 組蛋白去乙醯酶6抑制劑及其用途
CN107011238B (zh) * 2017-03-14 2020-05-01 北京化工大学 一类组蛋白去乙酰化酶抑制剂及其制备方法和用途
US10934255B2 (en) * 2017-04-26 2021-03-02 The Board Of Trustees Of The University Of Illinois Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same
CN109705015B (zh) * 2017-10-25 2022-05-24 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
CN108794469A (zh) * 2018-04-28 2018-11-13 通化师范学院 一种吡咯化合物的合成新工艺及抗肿瘤作用的用途
CN115636774B (zh) * 2022-12-01 2023-12-22 南开大学 一种贝利司他的合成方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288595A (en) * 1980-04-24 1981-09-08 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
WO2004078757A2 (en) * 2003-03-06 2004-09-16 Eisai Co., Ltd. Synthesis of 5-substituted 7-azaindoles and 7-azaidonines
WO2005013691A1 (en) * 2003-08-04 2005-02-17 Hemocorm Limited Use of boranocarbonates for the therapeutic delivery of carbon monoxide
CN1878464A (zh) * 2003-08-04 2006-12-13 黑莫科姆有限公司 一氧化碳的治疗性输送
WO2009137462A2 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Methods for treating cognitive disorders using inhibitors of histone deacetylase
WO2012058645A1 (en) * 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
WO2012106343A3 (en) * 2011-02-01 2012-10-04 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2013062344A1 (en) * 2011-10-28 2013-05-02 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
WO2015087151A1 (en) * 2013-12-12 2015-06-18 Chong Kun Dang Pharmaceutical Corp. Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
CN101263121A (zh) * 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
WO2011011186A2 (en) 2009-07-22 2011-01-27 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
US8119683B2 (en) * 2009-08-10 2012-02-21 Taipei Medical University Aryl substituted sulfonamide compounds and their use as anticancer agents
HUE033099T2 (en) * 2009-12-01 2017-11-28 Abbvie Inc Novel tricyclic compounds
CA2787784A1 (en) 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
TWI429628B (zh) * 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288595A (en) * 1980-04-24 1981-09-08 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
WO2004078757A2 (en) * 2003-03-06 2004-09-16 Eisai Co., Ltd. Synthesis of 5-substituted 7-azaindoles and 7-azaidonines
WO2005013691A1 (en) * 2003-08-04 2005-02-17 Hemocorm Limited Use of boranocarbonates for the therapeutic delivery of carbon monoxide
CN1878464A (zh) * 2003-08-04 2006-12-13 黑莫科姆有限公司 一氧化碳的治疗性输送
WO2009137462A2 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Methods for treating cognitive disorders using inhibitors of histone deacetylase
WO2012058645A1 (en) * 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
WO2012106343A3 (en) * 2011-02-01 2012-10-04 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2013062344A1 (en) * 2011-10-28 2013-05-02 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
WO2015087151A1 (en) * 2013-12-12 2015-06-18 Chong Kun Dang Pharmaceutical Corp. Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Discovery of 4-azaindoles as novel inhibitors of c-Met kinse;John Poter et al;《Bioorganic&Medicinal Chemistry Letters》;20090327;表1、表3 *
John Poter et al.Discovery of 4-azaindoles as novel inhibitors of c-Met kinse.《Bioorganic&Medicinal Chemistry Letters》.2009,第2780-2784页. *

Also Published As

Publication number Publication date
JP6726658B2 (ja) 2020-07-22
TWI573787B (zh) 2017-03-11
US20170057956A1 (en) 2017-03-02
WO2015157504A1 (en) 2015-10-15
US10246455B2 (en) 2019-04-02
EP3129373B1 (en) 2021-09-01
CN107001354A (zh) 2017-08-01
TW201609642A (zh) 2016-03-16
JP2017510660A (ja) 2017-04-13
EP3129373A4 (en) 2017-11-29
EP3129373A1 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
CN107001354B (zh) 组蛋白去乙酰酶抑制剂
JP7709378B2 (ja) Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法
CN102947268B (zh) 吲哚基或吲哚啉基羟肟酸化合物
CN112969696A (zh) 乙酰化书写器抑制剂的开发及其用途
JP2009539886A (ja) Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体
JP6615207B2 (ja) 複素環式化合物及びその使用
TWI849310B (zh) 用於腫瘤微環境免疫調節作用之組蛋白去乙醯化酶抑制劑
TWI684581B (zh) 與泛素化-蛋白酶體系統有關之化合物及醫藥組合物
CN117881657A (zh) 苯基-氨磺酰基-苯甲酸衍生物作为erap1调节剂
CN116589464B (zh) 嘧啶并环类化合物、其制备方法和应用
HK1181388B (en) Indolyl or indolinyl hydroxamate compounds
HK1181388A (en) Indolyl or indolinyl hydroxamate compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant